186 related articles for article (PubMed ID: 11252300)
1. Gait analysis in advanced Parkinson's disease--effect of levodopa and tolcapone.
Shan DE; Lee SJ; Chao LY; Yeh SI
Can J Neurol Sci; 2001 Feb; 28(1):70-5. PubMed ID: 11252300
[TBL] [Abstract][Full Text] [Related]
2. Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients.
Baas H; Beiske AG; Ghika J; Jackson M; Oertel WH; Poewe W; Ransmayr G
J Neurol Neurosurg Psychiatry; 1997 Oct; 63(4):421-8. PubMed ID: 9343116
[TBL] [Abstract][Full Text] [Related]
3. Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients.
Baas H; Beiske AG; Ghika J; Jackson M; Oertel WH; Poewe W; Ransmayr G
Neurology; 1998 May; 50(5 Suppl 5):S46-53. PubMed ID: 9591522
[TBL] [Abstract][Full Text] [Related]
4. Acute administration of levodopa-benserazide and tolcapone, a COMT inhibitor, Parkinson's disease.
Limousin P; Pollak P; Pfefen JP; Tournier-Gervason CL; Dubuis R; Perret JE
Clin Neuropharmacol; 1995 Jun; 18(3):258-65. PubMed ID: 8635184
[TBL] [Abstract][Full Text] [Related]
5. Effects of tolcapone, a catechol-O-methyltransferase inhibitor, on motor symptoms and pharmacokinetics of levodopa in patients with Parkinson's disease.
Yamamoto M; Yokochi M; Kuno S; Hattori Y; Tsukamoto Y; Narabayashi H; Tohgi H; Mizuno Y; Kowa H; Yanagisawa N; Kanazawa I
J Neural Transm (Vienna); 1997; 104(2-3):229-36. PubMed ID: 9203084
[TBL] [Abstract][Full Text] [Related]
6. Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: a multicenter, double-blind, randomized, placebo-controlled trial. Tolcapone Fluctuator Study Group I.
Kurth MC; Adler CH; Hilaire MS; Singer C; Waters C; LeWitt P; Chernik DA; Dorflinger EE; Yoo K
Neurology; 1997 Jan; 48(1):81-7. PubMed ID: 9008498
[TBL] [Abstract][Full Text] [Related]
7. Randomized trial of tolcapone versus pergolide as add-on to levodopa therapy in Parkinson's disease patients with motor fluctuations.
Koller W; Lees A; Doder M; Hely M;
Mov Disord; 2001 Sep; 16(5):858-66. PubMed ID: 11746615
[TBL] [Abstract][Full Text] [Related]
8. COMT inhibition by tolcapone further improves levodopa pharmacokinetics when combined with a dual-release formulation of levodopa/benserazide. A novel principle in the treatment of Parkinson's disease.
Gasser UE; Jorga K; Crevoisier C; Hovens SE; van Giersbergen PL
Eur Neurol; 1999; 41(4):206-11. PubMed ID: 10343151
[TBL] [Abstract][Full Text] [Related]
9. Randomized, placebo-controlled study of tolcapone in patients with fluctuating Parkinson disease treated with levodopa-carbidopa. Tolcapone Fluctuator Study Group III.
Adler CH; Singer C; O'Brien C; Hauser RA; Lew MF; Marek KL; Dorflinger E; Pedder S; Deptula D; Yoo K
Arch Neurol; 1998 Aug; 55(8):1089-95. PubMed ID: 9708959
[TBL] [Abstract][Full Text] [Related]
10. Tolcapone improves motor function in parkinsonian patients with the "wearing-off" phenomenon: a double-blind, placebo-controlled, multicenter trial.
Rajput AH; Martin W; Saint-Hilaire MH; Dorflinger E; Pedder S
Neurology; 1997 Oct; 49(4):1066-71. PubMed ID: 9339691
[TBL] [Abstract][Full Text] [Related]
11. Tolcapone added to levodopa in stable parkinsonian patients: a double-blind placebo-controlled study. Tolcapone in Parkinson's Disease Study Group II (TIPS II).
Dupont E; Burgunder JM; Findley LJ; Olsson JE; Dorflinger E
Mov Disord; 1997 Nov; 12(6):928-34. PubMed ID: 9399217
[TBL] [Abstract][Full Text] [Related]
12. Long-term comparative experience with tolcapone and entacapone in advanced Parkinson's disease.
Factor SA; Molho ES; Feustel PJ; Brown DL; Evans SM
Clin Neuropharmacol; 2001; 24(5):295-9. PubMed ID: 11586115
[TBL] [Abstract][Full Text] [Related]
13. Highlights of the North American and European experiences.
Goetz CG
Neurology; 1998 May; 50(5 Suppl 5):S15-6. PubMed ID: 9591517
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetics of levodopa in patients with Parkinson's disease treated with tolcapone.
Jorga K; Banken L; Fotteler B; Snell P; Steimer JL
Clin Pharmacol Ther; 2000 Jun; 67(6):610-20. PubMed ID: 10872643
[TBL] [Abstract][Full Text] [Related]
15. Clinical experience of tolcapone in advanced Parkinson's disease.
Canesi M; Zecchinelli AL; Pezzoli G; Antonini A
Neurol Sci; 2008 Dec; 29 Suppl 5():S380-2. PubMed ID: 19381768
[TBL] [Abstract][Full Text] [Related]
16. Tolcapone improves motor function in parkinsonian patients with the "wearing-off" phenomenon: a double-blind, placebo-controlled, multicenter trial.
Rajput AH; Martin W; Saint-Hilaire MH; Dorflinger E; Pedder S
Neurology; 1998 May; 50(5 Suppl 5):S54-9. PubMed ID: 9591523
[TBL] [Abstract][Full Text] [Related]
17. Tolcapone in stable Parkinson's disease: efficacy and safety of long-term treatment. The Tolcapone Stable Study Group.
Waters CH; Kurth M; Bailey P; Shulman LM; LeWitt P; Dorflinger E; Deptula D; Pedder S
Neurology; 1997 Sep; 49(3):665-71. PubMed ID: 9305320
[TBL] [Abstract][Full Text] [Related]
18. Tolcapone in stable Parkinson's disease: efficacy and safety of long-term treatment. Tolcapone Stable Study Group.
Waters CH; Kurth M; Bailey P; Shulman LM; LeWitt P; Dorflinger E; Deptula D; Pedder S
Neurology; 1998 May; 50(5 Suppl 5):S39-45. PubMed ID: 9591521
[TBL] [Abstract][Full Text] [Related]
19. Tolcapone, a selective catechol-O-methyltransferase inhibitor for treatment of Parkinson's disease.
Guay DR
Pharmacotherapy; 1999 Jan; 19(1):6-20. PubMed ID: 9917075
[TBL] [Abstract][Full Text] [Related]
20. Tolcapone, bromocriptine, and Parkinson's disease. French Tolcapone Study Group.
Agid Y; Destée A; Durif F; Montastruc JL; Pollak P
Lancet; 1997 Sep; 350(9079):712-3. PubMed ID: 9291909
[No Abstract] [Full Text] [Related]
[Next] [New Search]
